Findings in the Area of Mental Health Diseases and Conditions Reported from Hospital Center University of Toulouse (Use of the French National Health Insurance Information System for Research In the Field of Mental Health: Systematic Review and …): Mental Health Diseases and Conditions

2023 FEB 23 (NewsRx) -- By a News Reporter-Staff News Editor at Health & Medicine Business Daily -- New research on Mental Health Diseases and Conditions is the subject of a report. According to news reporting out of Toulouse, France, by NewsRx editors, research stated, “This systematic review registered in PROSPERO (CRD42021225296) aimed to describe the use of the French national health insurance information system, which covers the entire French population (67 million inhabitants), for research in the field of mental health. Three electronic databases and a journal hand-search identified 15 265 articles from January 1, 2003 (year of creation of the database) to October 31, 2020.”

Our news journalists obtained a quote from the research from the Hospital Center University of Toulouse, “Studies of any design were eligible for inclusion provided that they (i) made use of at least one component of the French health insurance database and (ii) focused on a topic in near and far connection with the field of mental health in France. Database used, design and methods, study period, population, key findings, and type of use for medical research were described. A total of 152 studies were included in the review analysis. There was an increase in the number of published articles over time throughout the studied period. Studies focusing on adults (n = 139) largely outnumbered those focusing on children and adolescents (n = 11). Pharmacoepidemiological studies were by far the most frequent (n = 123), followed by methodological studies (n = 23), epidemiological studies (n = 17), and health economics studies (n = 3). The most studied psychotropic drugs were antidepressants (n = 27), anxiolytics (n = 27), and opioids (n = 25) while fewer studies focused on methylphenidate (n = 6) and on mood stabilizers (n = 5). Few studies specifically focused on psychiatric disorders, mainly depression (n = 4), suicide (n = 4), and psychotic disorders (n = 3).”

According to the news editors, the research concluded: “This systematic review highlighted a relatively poor exploitation of the Systeme national des donnees de sante database in the field of psychiatric research with regard to the great possibilities it offers, with a clear lag in certain fields such as epidemiological or health economics studies and in specific populations, in particular children and adolescents.”

This research has been peer-reviewed.

For more information on this research see: Use of the French National Health Insurance Information System for Research In the Field of Mental Health: Systematic Review and Perspectives. Fundamental & Clinical Pharmacology, 2022;36(1):16-34. Fundamental & Clinical Pharmacology can be contacted at: Wiley, 111 River St, Hoboken 07030-5774, NJ, USA.

Our news journalists report that additional information may be obtained by contacting Alexis Revet, Hospital Center University of Toulouse, Serv Univ Psychiat Enfant & Adolescent, Toulouse, France. Additional authors for this research include Jean-Philippe Raynaud, Guillaume Moulis, Maryse Lapeyre-Mestre and Eric Bui.

The direct object identifier (DOI) for that additional information is: https://doi.org/10.1111/fcp.12696. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

(Our reports deliver fact-based news of research and discoveries from around the world.)